Board of Directors
KARMET- Phase 2b
RASMET – Phase 2a
Enterin is aiming to become the first company
in the world to develop a novel drug that
repairs the dysfunctional
in patients with neurodegenerative disease.
In preclinical models of Parkinson’s Disease,
and restores normal signaling between the gut and the brain.
Our lead molecule, ENT-01,
has recently met its primary endpoint
in a Phase 2b study for patients with Parkinson's Disease.
Our clinical data indicates that
repair of the gut-brain axis is able to
quality of life
by influencing multiple non-motor symptoms that affect patients with Parkinson’s Disease and other neurodegenerative conditions.
Watch an interview with one of Enterin’s founders,
Dr. Michael Zasloff, discussing a new hope
autism and other neurodegenerative diseases.
WATCH THE VIDEO